Introduction
Young ovarian cancer survivors face challenging decisions about managing premature menopause symptoms after treatment. The potential risks of estrogen hormone therapy (EHT) in hormone-sensitive cancers have remained unclear. This landmark study provides critical evidence about EHT’s safety profile across different ovarian cancer subtypes in patients under 60.
Study Design and Methodology
Specialty calculators
For clinical reference; use professional judgment.
